Samsung Bioepis Q1 sales surpass $362 mn in US, Europe

Q: How long will it take to read this news story?

The story "Samsung Bioepis Q1 sales surpass $362 mn in US, Europe" has 206 words across 14 sentences, which will take approximately 1 - 2 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Samsung Bioepis Q1 sales surpass $362 mn in US, Europe" was covered 2 weeks ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 0 news stories per day. It's most recent story was published 1 days ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23387967</li><li>URL: https://beamstart.com/news/samsung-bioepis-q1-sales-surpass-17306910947233</li></ul>

Korea Economic Daily Logo Korea Economic Daily 2w ago

Samsung Bioepis Q1 sales surpass $362 mn in US, Europe - Korea Economic Daily

Quick Summary:

Samsung Bioepis Co.reported that its quarterly overseas sales of key biosimilars exceeded 500 billion won ($362 million), according to figures released by its overseas distribution partners Biogen Inc.and Organon & Co.

This is reflected in parent company Samsung Biologics’ third quarter of this year report, which lists Samsung Bioepis’s sales at 330.3 billion won ($240 million).

The US-based Biogen and Organon stated that Samsung Bioepis’s six biosimilar products generated overseas revenue of $362.4 million in the third quarter.